Open Orphan Plc (GB:HVO) has released an update.
hVIVO plc, a leading specialist contract research organisation, has successfully passed all resolutions at its Annual General Meeting, signaling strong shareholder confidence. The company, known for its expertise in human challenge clinical trials for infectious and respiratory diseases, is growing rapidly and boasts a client base that includes top global biopharma companies. With new state-of-the-art facilities opening in Canary Wharf in 2024, hVIVO is set to host the world’s largest commercial human challenge trial unit, enhancing its already comprehensive range of clinical development services.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.
